抗瘤增效方对NSCLC化疗患者免疫功能及血清VEGF、CYFRA21-1的影响  

Effects of “Kangliu Zengxiao Decoction” on Immunological Functions and Serum VEGF and CYFRA21-1 in Patients with Non-small Cell Lung Cancer

作　　者：周卫东[1] 徐振晔[1] 王中奇[1] 朱晏伟[1] 王立芳[1] 

机构地区：[1]上海中医药大学附属龙华医院肿瘤科,上海200032

出　　处：《上海中医药杂志》2005年第3期6-8,共3页Shanghai Journal of Traditional Chinese Medicine

摘　　要：观察抗瘤增效方对非小细胞肺癌患者的近期疗效和免疫功能以及血清VEGF、CYFRA21 -1的影响。将50例非小细胞肺癌患者随机分为化疗组 24例,化疗+中药组 26例,均采用MVP方案或NP方案化疗 2个疗程,化疗+中药组在化疗同时口服中药抗瘤增效方。结果:化疗 +中药组肿瘤近期疗效为 73. 08%,优于化疗组的45 83% (P<0. 05);该组KPS评分提高稳定率为 88 46%,高于化疗组的 58. 33% (P<0. 01);T细胞总数、辅助性T细胞及NK细胞水平均高于化疗组,而抑制性T细胞水平及VEGF、CYFRA21 -1水平均低于化疗组。结论:中药抗瘤增效方能提高非小细胞肺癌化疗疗效,改善生活质量,增强免疫功能,抑制肿瘤细胞的活动。To observe the short-term clinical efficacy of “Kangliu Zengxiao Decoction” in treating non-small cell lung cancer (NSCLC) and its effects on serum VEGF and CYFRA21-1, 50 subjects were randomized into control group in which 24 cases were treated by chemotherapy and treatment group in which 26 cases were treated by chemotherapy and “Kangliu Zengxiao Decoction”. Two periods of treatment by NP or MVP scheme was employed in the two groups. Results: The clinical effect was better in treatment group (73.08%) than in control group (45.83%), P<0.05; the improvement and stabilization in KPS score was higher in treatment group (88.46%) than in control group (58.33%), P<0.01; the Decoction could increase the number of T-cell, auxiliary T-cell and NK cell, decrease the number of anti-T cell, and reduce the level of serum VEGF and CYFRA21-1. Conclusion: The Decoction can restrain the activity of tumor cells and ameliorate life quality by improving clinical efficacy and boosting immunological function.

关 键 词：抗瘤增效方 非小细胞肺癌 免疫功能 VEGF CYFR21-1 

分 类 号：R734.2[医药卫生—肿瘤]